Testosterone extended-release - GlaxoSmithKline
Alternative Names: T-8 oral testosterone - GlaxoSmithKline; Testosterone-extended-releaseLatest Information Update: 13 Nov 2021
At a glance
- Originator GlaxoSmithKline
- Developer GSK; University of Washington
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypogonadism
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hypogonadism(In volunteers) in USA (PO, Controlled release)
- 01 Jun 2012 GlaxoSmithKline completes a phase I trial in volunteers in USA (NCT01167829)
- 27 Oct 2010 GlaxoSmithKline completes enrolment in a phase I trial in volunteers in USA (NCT01167829)